Beijing Synlead Pharmaceutical Technology Development

Synlead Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a structure-based drug design (SBDD) platform to target metabolic diseases, oncology, and inflammatory conditions. Its lead candidate, SNLD11, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently being evaluated in Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Synlead aims to address significant unmet medical needs through the development of best-in-class and first-in-class oral medications. The company is backed by prominent venture capital firms including HighLight Capital and IDG Capital.